ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2019
The Uropathogenic Escherichia coli Subclone Sequence Type 131-H30 Is Responsible for Most Antibiotic Prescription Errors at an Urgent Care Clinic.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 35 citations in OpenAlex.
- PSK1, a bacteriophage with antibacterial activity against extended-spectrum-beta-lactamase-producing Escherichia coli sequence type 131 with serotype O25:H4.Archives of virology · 2025Article
- A First Report on Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Progress toward a vaccine for extraintestinal pathogenicInfection and immunity · 2024Article
- Gut residentmedRxiv : the preprint server for health sciences · 2024Article
- Clonal and resistance profiles of fluoroquinolone-resistant uropathogenicFrontiers in microbiology · 2024Article
- Increase in the community circulation of ciprofloxacin-resistant Escherichia coli despite reduction in antibiotic prescriptions.Communications medicine · 2023Article
- High Emergence of Multidrug-Resistant Sequence Type 131 Subclade C2 among Extended-Spectrum β-Lactamase (ESBL)-ProducingAntibiotics (Basel, Switzerland) · 2023Article
- Genomic Characterization of UropathogenicInternational journal of molecular sciences · 2023Article
- Colonization withPathogens (Basel, Switzerland) · 2023Article
- Increase in the Rate of Gut Carriage of Fluoroquinolone-Resistant Escherichia coli despite a Reduction in Antibiotic Prescriptions.Research square · 2023Article
- Treatment and Epidemiology of Third-Generation Cephalosporin-Resistant Urinary Tract Infections.Pediatrics · 2022Article
- The impact of the ST131 clone on recurrent ESBL-producing E. coli urinary tract infection: a prospective comparative study.Scientific reports · 2022Article
- Genomic insights into the circulation of pandemic fluoroquinolone-resistant extra-intestinal pathogenicMicrobial genomics · 2021Article
- Risk Factors for Extended-Spectrum-β-Lactamase-ProducingAnnals of laboratory medicine · 2021Article
- Compared with Cotrimoxazole Nitroxoline Seems to Be a Better Option for the Treatment and Prophylaxis of Urinary Tract Infections Caused by Multidrug-Resistant Uropathogens: An In Vitro Study.Antibiotics (Basel, Switzerland) · 2021Article
- Molecularly defined extraintestinal pathogenicVirulence · 2020Article
- A guide for urogynecologic patient care utilizing telemedicine during the COVID-19 pandemic: review of existing evidence.International urogynecology journal · 2020Review
- Genomic surveillance ofMicrobial genomics · 2020Article
- Pandemic Uropathogenic Fluoroquinolone-resistant Escherichia coli Have Enhanced Ability to Persist in the Gut and Cause Bacteriuria in Healthy Women.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Nitrofurantoin Combined With Amikacin: A Promising Alternative Strategy for Combating MDR UropathogenicFrontiers in cellular and infection microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundThe pandemic spread of antibiotic resistance increases the likelihood of ineffective empirical therapy. The recently emerged fluoroquinolone-resistant Escherichia coli sequence type (ST) 131-H30R subclone (H30) is a leading cause of multidrug-resistant urinary tract infection (UTI) and bloodstream infection worldwide.
methodsWe studied the relative impact of H30 on the likelihood that bacteria isolated from urine of urgent care patients would be resistant to the empirically prescribed antibiotic regimen for UTI.
resultsOf 750 urinalysis-positive urine samples from urgent care patients with suspected UTI, 306 (41%) yielded E. coli, from 35 different clonal groups (clonotypes). H30 predominated (14% prevalence overall), especially among older patients (age ≥70 years: 26%) and those with diabetes (43%) or urinary catheterization (60%). Resistance to the empirically selected antibiotic regimen occurred in 16% (40/246) of patients overall, 28% (20/71) of older patients, 30% (8/27) of patients with diabetes, 60% (3/5) of catheterized patients, and 71% (22/30) of those with H30. H30's contribution to such mismatched antibiotic selection was 55% overall, 70% among older patients, and 100% among patients with diabetes or a urinary catheter. Among patients with ≥2 of these factors (older age, diabetes, or urinary catheter), 24% of all urinalysis-positive urine samples yielded H30, with a 92% likelihood of resistance to the selected empirical therapy.
conclusionsThe multidrug-resistant H30 subclone of E. coli ST131 is responsible for the great majority of mismatched empirical antibiotic prescriptions for suspected UTI at an urgent care clinic among patients ≥70 years old or with diabetes or urinary catheterization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.